Key Insights

Highlights

Success Rate

98% trial completion (above average)

Published Results

41 trials with published results (15%)

Research Maturity

190 completed trials (70% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

1.5%

4 terminated out of 270 trials

Success Rate

97.9%

+11.4% vs benchmark

Late-Stage Pipeline

44%

118 trials in Phase 3/4

Results Transparency

22%

41 of 190 completed with results

Key Signals

41 with results98% success

Data Visualizations

Phase Distribution

238Total
Not Applicable (45)
Early P 1 (2)
P 1 (37)
P 2 (36)
P 3 (82)
P 4 (36)

Trial Status

Completed190
Unknown47
Recruiting14
Not Yet Recruiting10
Terminated4
Active Not Recruiting3

Trial Success Rate

97.9%

Benchmark: 86.5%

Based on 190 completed trials

Clinical Trials (270)

Showing 20 of 20 trials
NCT03945305Not ApplicableRecruitingPrimary

Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension

NCT06778239Recruiting

Childhood-Onset Essential Hypertension Natural History Study

NCT07704697Phase 3CompletedPrimary

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan

NCT07704684Phase 3CompletedPrimary

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine

NCT07700875Phase 2CompletedPrimary

A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

NCT07685054Not Yet RecruitingPrimary

To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.

NCT05503953Phase 3CompletedPrimary

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

NCT07577323Not ApplicableNot Yet RecruitingPrimary

Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension

NCT06682000Phase 3Completed

Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension

NCT01566188Not ApplicableCompletedPrimary

Vascular Impact of Omega-3 in Metabolic Syndrome

NCT06671392Phase 3CompletedPrimary

A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

NCT03857490Not ApplicableCompletedPrimary

Heat Therapy in Older Hypertensive Women

NCT06287580Early Phase 1CompletedPrimary

Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.

NCT07433790Not ApplicableCompleted

Mat Pilates With Paced Breathing Versus Diaphragmatic Breathing in Stage II Hypertension

NCT07424118Not ApplicableNot Yet RecruitingPrimary

REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription

NCT07421414Phase 1Not Yet RecruitingPrimary

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions

NCT07421375Phase 1Not Yet RecruitingPrimary

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions

NCT07421401Phase 1Not Yet RecruitingPrimary

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions

NCT07421388Phase 1Not Yet RecruitingPrimary

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions

NCT06041529Phase 4Active Not RecruitingPrimary

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Scroll to load more

Research Network

Activity Timeline